Hypermarcas (OTCMKTS:HYPMY) Sets New 1-Year Low – Time to Sell?

Hypermarcas (OTCMKTS:HYPMY)’s stock price reached a new 52-week low during trading on Monday. The stock traded as low as $3.39 and last traded at $3.39, with a volume of 31,720 shares traded. The stock had previously closed at $5.40.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy”.

Hypermarcas Price Performance

The stock has a 50 day moving average price of $4.66 and a 200 day moving average price of $4.44.

Hypermarcas (OTCMKTS:HYPMY) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01. As a group, analysts expect that Hypermarcas will post 0.51 earnings per share for the current year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.